I don’t know what the bottlenecks are in vaccine manufacturing and distribution. I also know a lot of other nations have the infrastructure to manufacture vaccines and I assume/hope they are doing the same thing all over the world.
If the federal government took charge and made businesses make manufacturing and distribution of the vaccine a priority how fast could vaccines get produced in the US alone?
What are the bottlenecks in vaccine manufacture and distribution?
Excellent question.
Can Biden’s people get a plant that makes vaccine vials to instantly throw on a second or third shift? Or is that already done, so more vials for COVID can only mean something else goes into shortage?
In WWII, in the U.S., there were noticeable shortages. People who complained were told “Don’t you know there’s a war on?” In this case, the shortage would be much more brief.
What is it that needs to go short to win the vaccine war? Neither you nor I know.
When the census ended, why didn’t the government offer competent census takers training in giving shots? They could have been working Christmas, and today. Instead, exhausted nurses today stayed home, or treated people with COVID.
It’s a little late to train staff now.
doctors, nurses and pharmacists can all administer vaccinations I believe. that’s about five million workers. I don’t think that’s the bottleneck.
I think it’s more manufacturing the vaccine that’s the bottleneck. but can’t Biden tell private biotechnology companies with the equipment to stop producing whatever they’re making and start making vaccines?
Don’t some of the “ingredients” in a vaccine have to be grown/cultured? No amount of extra labor or floor space is going to make that happen faster. You can’t buy time.
With the DPA couldn’t Biden make other biotech companies with the infrastructure switch over to growing/culturing those ingredients?
I don’t know what all goes into the manufacture of RNA base pairs.
This NPR story from yesterday indicates that administration is, indeed, one of the bottlenecks.
Also, while, yes, most (if not all) doctors, nurses, and pharmacists are trained and capable of administering vaccines, many of them are busy doing other things (including taking care of record numbers of COVID patients). I’ve read several stories indicating that local health officials are looking at ideas like recruiting retired medical professionals to do the vaccine administration.
I imagine that pretty much every facility capable of manufacturing vaccine is already doing so. The problem is that that’s a limited number. You can convert a factory that makes cars into a factory that makes tanks, but you can’t convert a factory that makes cars into a factory that makes vaccines.
You can’t even make a factory that makes standard vaccines suddenly able to produce mRNA vaccines.
Not so much with the mRNA vaccine as with traditional vaccines. I don’t know what the process is, but apparently it’s much faster, and requires a completely different production facility.
Our local vaccine manufacturer in Melbourne.Australia has reported that it would take a big chunk of a year to bring the new production method on line, by which time they don’t believe there will be a vaccine shortage.
The local vaccine that they were hoping to produce has been withdrawn, but they are still hoping that they will be able to produce one of the other non-mRNA vaccines when they are approved
Which also answers the OP: if the American government took over vaccine production, they could direct companies to build production facilities, which, by the time they were available, would be useless.
According to this article, they break down the manufacture and distribution of mRNA vaccines into six steps. They label step 4 as the bottleneck.
https://blogs.sciencemag.org/pipeline/archives/2021/02/02/myths-of-vaccine-manufacturing
Step One: Produce the appropriate stretch of DNA, containing the sequence that you need to have transcribed into mRNA. This is generally done in bacterial culture.
Step Two: Produce that mRNA from your DNA template using enzymes in a bioreactor.
Step Three: Produce the lipids that you need for the formulation. Some of these are pretty common (such as cholesterol), but the key ones are very much not (more on this below).
Step Four: take your mRNA and your lipids and combine these into lipid nanoparticles (LNPs). I have just breezed past the single biggest technological hurdle in the whole process, and below you will learn why it’s such a beast.
Step Five: combine the LNPs with the other components of the formulation (phosphate buffers, saline, sucrose and such) and fill those into vials.
Step Six: get those vials into trays, into packages, into boxes, into crates, and out the door into trucks and airplanes
Ah, but now we get back to Step Four. As Neubert says, “Welcome to the bottleneck!” Turning a mixture of mRNA and a set of lipids into a well-defined mix of solid nanoparticles with consistent mRNA encapsulation, well, that’s the hard part. Moderna appears to be doing this step in-house, although details are scarce, and Pfizer/BioNTech seems to be doing this in Kalamazoo, MI and probably in Europe as well. Everyone is almost certainly having to use some sort of specially-built microfluidics device to get this to happen – I would be extremely surprised to find that it would be feasible without such technology. Microfluidics (a hot area of research for some years now) involves liquid flow through very small channels, allowing for precise mixing and timing on a very small scale. Liquids behave quite differently on that scale than they do when you pour them out of drums or pump them into reactors (which is what we’re used to in more traditional drug manufacturing). That’s the whole idea. My own guess as to what such a Vaccine Machine involves is a large number of very small reaction chambers, running in parallel, that have equally small and very precisely controlled flows of the mRNA and the various lipid components heading into them. You will have to control the flow rates, the concentrations, the temperature, and who knows what else, and you can be sure that the channel sizes and the size and shape of the mixing chambers are critical as well.
These will be special-purpose bespoke machines, and if you ask other drug companies if they have one sitting around, the answer will be “Of course not”. This is not anything close to a traditional drug manufacturing process. And this is the single biggest reason why you cannot simply call up those “dozens” of other companies and ask them to shift their existing production over to making the mRNA vaccines. There are not dozens of companies who make DNA templates on the needed scale. There are definitely not dozens of companies who can make enough RNA. But most importantly, I believe that you can count on one hand the number of facilities who can make the critical lipid nanoparticles. That doesn’t mean that you can’t build more of the machines, but I would assume that Pfizer, BioNTech, Moderna (and CureVac as well) have largely taken up the production capacity for that sort of expansion as well.